OncoFluor

OncoFluor is a biotechnology company focused on developing advanced fluorescence-guided surgery (FGS) technologies to improve the precision of cancer resections. The company's core technology utilizes tumor-specific fluorescent probes that are activated by enzymes, such as cathepsins, which are overexpressed in the microenvironment of various solid tumors. By providing real-time, high-contrast visualization of malignant tissues, OncoFluor aims to assist surgeons in achieving complete tumor removal while sparing healthy tissue. Their lead programs target a broad range of indications, including breast, lung, and gastrointestinal cancers, leveraging a platform designed for seamless integration into existing surgical workflows.